Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults

Exclusion Criteria

• •1. Current acute febrile illness.
• •2. Clinically significant cardiac, respiratory, or rheumatologic disease, in the opinion of the Investigator.
• •3. Pregnant or breast-feeding.
• •4. Laboratory evidence of infection with Hepatitis B/C or HIV.
• •5. History of chikungunya virus infection.
• •6. Travel to a World Health Organization-designated chikungunya-endemic region within 30 days prior to Day 1.
• •7. History of allergic reaction to any component of CHIKV-VLP vaccine, Diluent, or Alhydrogel®.
• •8. Inability to discontinue systemic immunomodulatory or immunosuppressive medications 30 days prior to Day 1.
• •9. Received or plans to receive any licensed vaccine from 30 days prior to Day 1 through Day 57.
• •10. Received or plans to receive an investigational agent from 30 days prior to Day 1 through the duration of study participation.
• •11. Any other condition that, in the opinion of the Investigator, creates an unacceptable risk to the subject.
• •12. Any other condition that, in the opinion of the Investigator, may interfere with the conduct of the study or the validity of the data.
• •13. Any other condition that, in the opinion of the Investigator, creates an unacceptable safety risk for apheresis (Group 9 \& 10 only).
• •14. Restricted venous access that would prevent the collection of PBMCs, plasma, and lymphocytes necessary for participation (Group 9 \& 10 only).
• •15. Weight \< 110 pounds (Group 9 \& 10 only)